Mercedes
Salgado Fernández
Complexo Hospitalario Universitario de Ourense
Orense, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Ourense (21)
2024
-
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study
Clinical and Translational Oncology
-
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651
2023
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2022
-
Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer
Genomics, Vol. 114, Núm. 6
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Establishing an Expert Consensus on Key Indicators of the Quality of Life among Breast Cancer Survivors: A Modified Delphi Study
Journal of Clinical Medicine, Vol. 11, Núm. 7
-
Venous Thromboembolism In Cancer Patients: “From Evidence to Care”
Clinical and Applied Thrombosis/Hemostasis, Vol. 28
2021
-
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839
-
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
BMC Cancer, Vol. 21, Núm. 1
2020
-
First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial
Clinical and Translational Oncology, Vol. 22, Núm. 4, pp. 495-502
-
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
International Journal of Colorectal Disease, Vol. 35, Núm. 4, pp. 739-746
2018
-
From first line to sequential treatment in the management of metastatic pancreatic cancer
Journal of Cancer, Vol. 9, Núm. 11, pp. 1978-1988
-
Management of unresectable, locally advanced pancreatic adenocarcinoma
Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 113-118
-
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
British Journal of Cancer
-
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study
BMC Cancer, Vol. 18, Núm. 1
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2014
2011
-
Evaluación ecónomica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera línea de cáncer gástrico avanzado en España
Pharmacoeconomics - Spanish Research Articles, Vol. 8, Núm. 2, pp. 51-58